Navigation Links
Light Sciences Oncology Raises $40.1 Million in Series C Financing

Proceeds to Fund Completion of Phase III Trials of Light Infusion Therapy in Hepatocellular Carcinoma and Metastatic Colorectal Cancer and Phase I/II

and Phase IIa Benign Prostatic Hyperplasia Studies

BELLEVUE, Wash., July 15 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO), a privately held company developing Light Infusion Therapy(TM) (Litx(TM)) to treat cancer and other conditions, today announced that it has raised $40.1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed.

LSO plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme (brain cancer), and early stage clinical trials in benign prostatic hyperplasia (BPH).

"We are approaching exciting milestones in the development of Litx, including the completion of enrollment in our Phase III primary liver cancer trial," said Llew Keltner, M.D., Ph.D., president and chief executive officer of Light Sciences Oncology. "The Series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner."

Leerink Swann LLC acted as exclusive placement agent and exclusive financial advisor in connection with the transaction.

About Light Sciences Oncology

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)) to provide safer and more effective treatment for cancer and other conditions. In addition to the Phase III trials in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential therapeutic applications of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease and dermatology. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.


Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer


Llew Keltner, M.D., Ph.D.

President and CEO


SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
4. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
5. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
6. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
10. Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 ... directed at up to 10 G protein-coupled receptor (GPCR) ... ) to research and develop potential new medicines directed ... across multiple therapeutic areas. --> Heptares Therapeutics ... company and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... leading provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today ... Partner Program with competencies in the Application Development, demonstrating a “best-in-class” ability ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related changes are ... likely to include new codes for spine and hip X-rays, paravertebral facet blocks ... of code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute of Ultrasound ... process that allows practices to demonstrate that they meet or exceed nationally ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable ... ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a ... to enhance the benefits of a standard walker to improve the user’s quality of ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , a ... Chris Hafey and Claude Hooton to its board of directors. The announcement comes ... (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from being ...
Breaking Medicine News(10 mins):